Subjects receiving monoamine oxidase (MAO) inhibitors within  days of study enrollment (epacadostat increases serotonin levels, theoretically increasing the risk of serotonin syndrome, although this has not been reported in any ongoing clinical studies to date)
Patients requiring treatment with other anti-depressive medications including the selective and non-selective monoamine oxidase (MAO) inhibitors (including linezolid),  hydroxytryptamine (HT) receptor agonists (triptans), tryptophan or antidopaminergic agents (anti-psychotics, metoclopramide, promethazine, haloperidol)
Receipt of monoamine oxidase inhibitors (MAOIs), UGTA inhibitors, or melatonin supplements
Has had monoamine oxidase inhibitors within  days before screening
Have contraindications to the use of pressor agents (e.g., SC epinephrine), notably monoamine oxidase inhibitor (MAOI) use.
Concurrent therapy with monoamine oxidase inhibitors (MAOI), selective serotonin reuptake inhibitors (SSRI), or other tricyclic antidepressants (TCA) or use within  weeks study start
Receipt of monoamine oxidase inhibitors (MAOIs) within  days before first dose of study treatment
Patients must not be taking any contraindicated medications listed on the duloxetine package insert including the following: phenothiazines, propafenone, flecainide, linezolid, or anticoagulation medication (e.g., heparin, warfarin); treatment with monoamine oxidase (MAO) inhibitor within  days prior to registration
Patients who are receiving monoamine oxidase (MAO) inhibitors
Part : on monoamine oxidase inhibitors, tricyclic antidepressants, or clonidine
Has received monoamine oxidase inhibitors within  days prior to starting study
Current use of selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), monoamine oxidase (MAO) inhibitor, tramadol or trazadone; or use of these agents within  days
Use of monoamine oxidase inhibitors (MAOI)s and selective serotonin reuptake inhibitor (SSRIs) within the last  weeks or history of serotonin syndrome
Therapy with monoamine oxidase inhibitors (MAOIs) and selective serotonin reuptake inhibitor (SSRIs) within the last  weeks or history of serotonin syndrome
Monoamine oxidase (MAO) inhibitor use within the past  weeks or prior evidence of serotonin syndrome
Monoamine oxidase inhibitors.
Patients taking monoamine oxidase (MAO)-inhibitors or antipsychotic medications
Patient has taken monoamine oxidase inhibitors (MAOI) in the past two weeks
Concurrent therapy with a Selective Serotonin Reuptake Inhibitor (SSRI), tricyclic antidepressant, or Monoamine Oxidase Inhibitor (MAOi); clinical judgment should be used in a decision to discontinue antidepressants; a minimum of a  week washout period is required for any tricyclic or related antidepressant, or any SSRI ( weeks for paroxetine or sertraline,  weeks for fluoxetine); minimum  week washout for any MAOi
Patients who discontinue monoamine oxidase (MAO)-inhibitor (I)s within  days prior to starting the investigational drug
Concurrent use of monoamine oxidase inhibiting (MAOI) medication.
Patient is currently receiving or has received another investigational agent within  days or monoamine oxidase inhibitor within  days prior to Lazanda administration
Recently started on anti-depressant medications (past one month for those on selective serotonin reuptake inhibitors [SSRI] and past two months for those started on monoamine oxidase inhibitors [MAOI])
Patients taking monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, clonidine, psychostimulants, concurrent steroids or other medications specifically for fatigue
Use of monoamine oxidase inhibitors (MAOI) inhibitors
History of grade  depression or anxiety or treatment with antidepressants, antipsychotics or monoamine oxidase inhibitor (MAO) inhibitors within  days of registration
Need monoamine oxidase inhibitors, tricyclic antidepressants, or clonidine
Need monoamine oxidase inhibitors, tricyclic antidepressants, or clonidine
Currently receiving phenobarbital, diphenylhydantoin, primidone, phenylbutazone, monoamine oxidase inhibitors (MAOIs), clonidine and tricyclic antidepressant drugs
Current use or use within past two weeks of an monoamine oxidase inhibitor (MAOI)
Previous therapy with urate oxidase
Use of monoamine oxidase inhibitors within  days of study entry
